

Technology Advisory Interests Register

Topic: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
David Meads	TAC Committee Member	Financial	My Department and I have recently been funded by Johnson and Johnson to conduct work on the iFIT trial in Myeloma.	30/05/2025 02/08/2025	It was agreed that David's declaration would not prevent them from participating in discussions on this appraisal
Giles Monnickendam	TAC Committee Member	Financial	I have received honoraria from Janssen Cilag Ltd for attending an advisory board concerning relapsed refractory multiple myeloma.	07/08/2025 10/10/2025	It was agreed that Giles's declaration would not prevent them from participating in discussions on this appraisal
Simon McNamara	TAC Committee Member	Financial	GSK have an ongoing phase 3 trial of niraparib + pembrolizumab maintenance therapy following chemotherapy and pembrolizumab induction therapy for 1L metastatic non-small cell lung cancer (i.e., a first line maintenance study). This study excludes patients with EGFR mutations (i.e., the population for the second two topics).	14/10/2025	It was agreed that Simon's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	TAC Committee Member	Financial	Through my salaried role we're about to start a project with Johnson & Johnson, concerning their in-development treatment for geographic atrophy (an ophthalmological condition).	29/10/2025	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal
Professor Gini Harrison	Expert	Financial	Research Trustee at EGFR+ UK who have received £3,508 from Janssen to cover some of our patient support activities.	15/01/2025 13/08/2025	It was agreed that Professor Harrison's declaration would not prevent them from providing expert advice to the committee
			EGFR+ UK have received funding from Johnson & Johnson to support patient outreach work.	12/11/2025	
Professor Sanjay Popat	Expert	Financial	<ul style="list-style-type: none"> Investigator on company sponsored trials; Consultant to company in advisory boards on drug development; Speaker at company-sponsored symposia. Honoraria as consultant to multiple companies in field of thoracic malignancy/genomics: Anheart, Amgen, AstraZeneca, Bayer, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GlaxoSmithKline, 	15/05/2025 13/08/2025 12/11/2025	It was agreed that Professor Popat's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Non-financial	<p>Guardant Health, Janssen, Lilly, Merck KGaA, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Takeda, Turning Point Therapeutics.</p> <ul style="list-style-type: none"> Honoraria from Janssen totalling £3K included consultancy for this product and other licensed/unlicensed drugs/technologies. <p>Advisor to Charities: ALK Positive UK, Lung Cancer Europe, Ruth Strauss Foundation Board of Directors: Mesothelioma Applied Research Foundation Leadership: BTOG Steering Committee Chair, ETOP Foundation Council Member</p>		
Adam P Januszewski PhD MRCP	Expert	Indirect - financial	<p>Received grants from Gilead, Roche</p> <p>Received honoraria from AstraZeneca, Johnson & Johnson, MSD, Janssen, Pfizer, Bayer and Roche; Participated on a data safety monitoring board or advisory board</p>	<p>18/02/2025</p> <p>13/08/2025</p> <p>12/11/2025</p>	It was agreed that Adam's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			for BMS, AstraZeneca, Pfizer, and MSD		